NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Earnings for NewAmsterdam Pharma Company N.V. (NAMS)
Earnings in 2023 (TTM): $-160,245,078
According to NewAmsterdam Pharma Company N.V.'s latest financial reports the company's current earnings (TTM) are $-160,245,078. The earnings displayed on this page is the company's Pretax Income.
Earnings history of NewAmsterdam Pharma Company N.V.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-160,245,078 | $-160,269,534 |
| 2022 | $-21,137,892 | $-21,137,892 |
| 2021 | $-36,712,301 | $-36,712,301 |
| 2020 | $-5,749,000 | $-5,749,000 |